The Effect of PEMF for Patients With Quadriceps Muscle Weakness After ACLR

December 13, 2023 updated by: Prof. Tim-Yun Michael ONG, Chinese University of Hong Kong

A Double-Blinded, Randomized-Controlled-Trial to Investigate the Effect of Pulsed Electromagnetic Field (PEMF) for Patients With Quadriceps Weakness After Anterior Cruciate Ligament Reconstruction (ACLR)

In Hong Kong, over 3000 Anterior Cruciate Ligament Reconstructions (ACLR) are performed each year in order to restore knee function after an ACL injury. The ultimate goal of ACLR is to fulfil the return-to-play (RTP) criteria. Despite successful surgery and a demanding rehabilitation process, some athletes still fail to comply to RTP. For those who achieve RTP, 23% of those who return to their sports would suffer a second ACL injury.

Quadriceps muscle strength is one of the key determinants for a patient's successful return- to-play after ACLR. Quadriceps muscle atrophy can persist beyond the completion of the rehabilitation program in almost half the patients and the reason behind this is still unknown. Therefore, there is need to find a more effective way to increase quadriceps strength.

There are emerging evidences showing that pulsed electromagnetic field (PEMF) can modulate mitochondrial activities for muscle gain. PEMF exposure on top of regular exercise training may promote muscle regeneration and tissue healing.

This study aims to conduct a double-blinded, randomized controlled trial to investigate the effects of PEMF treatment during the late postoperative period on quadriceps muscle strength in ACL injured patient. Muscle endurance could only be investigated in late postoperative period. The investigators hypothesize that PEMF treatment is effective to reduce muscle weakness and promote gain in quadriceps muscle strength in ACLR patients.

Based on the aim of this study, adult patients (aged 18-30) with a unilateral ACL injury, total quadriceps muscle volume is equal or morn than 7% deficit on involved leg compared with uninvolved leg, sporting injury with a Tegner score of 7+, both knees without a history of injury/prior surgery will be recruited. To estimate the improvement of patients, Isokinetic muscle assessment, ultrasound imaging and MRI for quadriceps muscle thickness, self-reported outcomes with questionnaires, KT-1000 for knee laxity and biomechanical analysis, Xtreme CT for Bone mineral density will be performed.

To investigate the mechanism of PEMF therapy on increasing quadriceps strength, samples of blood serum will be draw before and after intervention.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hong Kong, Hong Kong
        • The Chinese University of Hong Kong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Aged 18-50 with a unilateral ACL injury
  2. Sporting injury with a Tegner score of 7+
  3. LSI for quadriceps strength <70% of the contralateral leg at 4 months post-up
  4. Both knees without a history of injury/prior surgery

Exclusion Criteria:

  1. Ages smaller than 18 years old or greater than 50 years old
  2. Any concomitant bone fracture, major meniscus injury or full-thickness chondral injuries requiring altered rehabilitation program post-op
  3. Preoperative radiographic signs of arthritis
  4. Metal implants that would cause interference on MRI
  5. Non-HS graft for ACLR
  6. Patient non-compliance to the rehabilitation program
  7. Pregnancy or possibility of pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment group
Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
Sham Comparator: Sham group
Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of peak torque of Isokinetic muscle strength
Time Frame: pre intervention, 4weeks, 8 weeks and 8 months after the commencement of intervention
The peak torque in N will be the single highest repetition value within the 30 repetitions in the isokinetic muscle strength test.
pre intervention, 4weeks, 8 weeks and 8 months after the commencement of intervention
Change of Fatigue index of isokinetic muscle strength
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
The Fatigue index (F.I) can be used to calculated the percent decrease for each variable which reflected the muscle endurance.
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ground reaction force
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
The Kinetic variables including vertical and horizontal ground reaction force (GRF) will be evaluated by a synchronized force plate at the centre of the capture volume at 1000Hz.
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Knee Joint moments
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
The kinematics will be assessed by the skin marker-based motion analysis system with the lower-body marker setup followed the OSTRC standard using 16-camera and 16 reflective skin marker during the single leg squat and single leg hop test.
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Single leg hop distance
Time Frame: 4weeks, 8 weeks and 8 months after the commencement of intervention
The average of single leg hop distance in cm with three attempts will be measured during the single leg hop test.
4weeks, 8 weeks and 8 months after the commencement of intervention
MRI Muscle thickness
Time Frame: pre PEMF intervention and 8 weeks after the commencement of intervention
Muscle volumes of quadriceps muscle are measured using a 1.5 or 3.0 Tesla MRI Scanner. Axial (3mm thick cut) T1W images are obtained from the anterior superior iliac spine (ASIS) to the patella. Quadriceps muscles were manually outlined in each axial slice. Muscle volume was calculated by summing all of the slice-multiplied by slice thickness. The quality of the muscle is assessed by analyzing the fat content of the muscle mass using a technique that has been reported by Reeder et al. Scans will be performed on both legs before the start of the PEMF treatment (4 months post-op) and only on the injured side repeated after the completion of the 8 weeks PEMF treatment (6 months post-op). The uninjured side will be used as a reference for 'normal volume'.
pre PEMF intervention and 8 weeks after the commencement of intervention
Ultrasound imaging muscle thickness
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
The Aixplorer® ultrasound system and a linear transducer probe with a bandwidth of 2-10 MHz were used to measure the muscle thickness of Vastus Medialis (VM), Vastus Lateralis (VL), and Rectus Femoris (RF) on both the injured and uninjured leg. Participants laid supine on a treatment table for the assessment. A measuring tape was used to locate VM, VL, RF and the patella by palpation, consequently marked with a pen for reference. RF was marked at 1/2 of the distance from the anterior superior iliac spine (ASIS) to the superior pole of the patella, VM was located at 1/5 of the distance away from the midpoint of the medial patella border to the ASIS, and VL was noted at 1/3 of the distance from the midpoint of the lateral patella border to the ASIS. After locating the anatomical points, excess contact gel was applied on these points. The transducer probe was aligned in the transverse plane and moved along the entire muscle bundle to capture a view of the VM, VL and RF.
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Serum myokine evaluation
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Phlebotomy (5ml) will be performed on the day before PEMF treatment, at 4- and 8- weeks after commencement of treatment, and at 8 months after the commencement of intervention. The serum will be prepared by centrifugation and kept in a -80o freezer until use. Quantitative analysis for myokines and proteins related to muscle metabolism will be performed by Human Myokine Magnetic Bead Panel (Millipore) with Bioplex-200 bead-based suspension assay system (LKSIHS core facilities), or enzyme-linked immunosorbent assay (ELISA) and report with pg/ml. These include Brain-derived neurotrophic factor (BDNF), Fibroblast growth factor-21 (FGF-21), Interleukin-6 (IL-6), IL-15, Irisin, Myostatin (MSTN)/GDF8, Insulin-like growth factor 1 (IGF-1), FGF-2, IL-8, Follistatin, Musclin, Myonectin, Decorin, Meteorinlike, Osteopontin, Secreted protein acidic and rich in cysteine (SPARC), Klotho, Procollagen type III N-terminal peptide (P3NP), and C- terminal of troponin T1 (TNNT1).
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Passive Knee laxity
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
To measure anterior-posterior knee laxity, the KT-1000 knee ligament arthrometer (MEDmetric Corp, San Diego, CA, USA) will be used. A manual force test will be applied until a 30lb sound signal is activated. Three trials will be performed. A side difference of 3 mm above is considered clinically relevant.
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Reaming size of the bone
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
The reaming size of the bone in mm on the involved side will be scanned by XtremeCT II which provides an analysis of bone microarchitecture at human peripheral sites with high spatial resolution and low exposure to radiation.
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Visual Analogue Scale
Time Frame: Before and after 1st - 16th of PEMF treatment
The subjective measurement for chronic and acute pain will be recorded by the Visual Analogue Scale (VAS). VAS consists of a 10-cm line which represents the continuum between "painless" and "worst pain from 0 cm to 10 cm. The subject will be asked to draw a mark of it before and after each PEMF treatment session.
Before and after 1st - 16th of PEMF treatment
Tegner activity score
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
This is an activity level scaled from 1 (low activity) to 10 (high activity).
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
International Knee Documentation Committee
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Consists of 10 questions on symptoms and activity ranging from 0 to 100 where 100 implies perfect knee function.
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Lysholm knee scoring system
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Consists of eight items, total score ranging from 0 to 100 where higher scores indicate a better outcome with fewer symptoms or disability.
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
International Physical Activity Questionnaire
Time Frame: pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention
Consists of four items recording the subject's time of spending on physical activities during the past 7 days with a validated Chinese version of the quantitative physical activity questionnaire, and the physical activity level will be evaluated by Metabolic Equivalent of task(MET) per minute and classified as physical level with Low, Moderate or High.
pre PEMF treatment , 4weeks, 8 weeks and 8 months after the commencement of intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Michael Tim-Yun ONG, Chinese University of Hong Kong

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2021

Primary Completion (Estimated)

September 1, 2025

Study Completion (Estimated)

September 1, 2025

Study Registration Dates

First Submitted

November 23, 2021

First Submitted That Met QC Criteria

January 5, 2022

First Posted (Actual)

January 11, 2022

Study Record Updates

Last Update Posted (Estimated)

December 15, 2023

Last Update Submitted That Met QC Criteria

December 13, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All IPD that underlie results in a publication

IPD Sharing Time Frame

starting 6 months after publication

IPD Sharing Access Criteria

Journal reviewers

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anterior Cruciate Ligament Injuries

Clinical Trials on Pulse Electromagnetic Field

3
Subscribe